

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 July 2020 (23.07.2020)



(10) International Publication Number
WO 2020/146946 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 37/02 (2006.01)
A61K 39/395 (2006.01) A61P 37/06 (2006.01)
A61P 29/00 (2006.01) C12N 15/13 (2006.01)
A61P 35/00 (2006.01) C12P 21/08 (2006.01)
A61P 35/02 (2006.01)

(21) International Application Number:

PCT/CA2020/050042

(22) International Filing Date:

16 January 2020 (16.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/794,064 18 January 2019 (18.01.2019) US

(71) Applicant: **UNIVERSITY HEALTH NETWORK**
[CA/CA]; 190 Elizabeth Street, R. Fraser Elliot Building -
Room 1S-417, Toronto, Ontario M5G 2C4 (CA).

(72) Inventors: **BROKX, Richard**; c/o University Health Net-
work, 190 Elizabeth Street, R. Fraser Elliot Building -
Room 1S-417, Toronto, Ontario M5G 2C4 (CA). **MASON,**
Jacqueline M.; c/o University Health Network, 190 Eliza-
beth Street, R. Fraser Elliot Building -Room 1S-417, Toron-
to, Ontario M5G 2C4 (CA). **BRAY, Mark R.**; c/o Univer-

sity Health Network, 190 Elizabeth Street, R. Fraser Elliot
Building - Room 1S-417, Toronto, Ontario M5G 2C4 (CA).


(74) Agent: **BOWN, Christopher** et al.; GOWLING WLG
(CANADA) LLP, Suite 2600, 160 Elgin Street, Ottawa, On-
tario K1P 1C3 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: LILRB3-BINDING MOLECULES AND USES THEREFOR

FIGURE 2



(57) Abstract: The invention provides novel anti-LILRB3 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation. This invention can also be used to modulate osteoclast differentiation.

[Continued on next page]

WO 2020/146946 A1

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*